Oral pill challenge to injection for rare blood disease shows promise
NCT ID NCT06799546
Summary
This completed Phase 3 trial tested if a new oral tablet called HSK39297 could work as well as the standard injected drug (eculizumab) for people with a rare blood disease called PNH who had never tried this type of medicine before. The main goal was to see if the pill could safely raise and maintain patients' hemoglobin levels without needing blood transfusions. Researchers directly compared the two treatments in 73 adult patients to measure which was better at controlling the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PNH are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, 210029, China
-
The First Affiliated Hospital, College of Medicine, Zhejiang University
Hangzhou, Zhejiang, 310003, China
Conditions
Explore the condition pages connected to this study.